Holocene Advisors LP Takes Position in Waters Corporation $WAT

Holocene Advisors LP bought a new position in shares of Waters Corporation (NYSE:WAT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 308,491 shares of the medical instruments supplier’s stock, valued at approximately $92,489,000. Holocene Advisors LP owned about 0.52% of Waters as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of WAT. Integrated Wealth Concepts LLC increased its holdings in Waters by 2.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Waters by 5.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock valued at $189,000 after buying an additional 35 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Waters by 1.8% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock worth $679,000 after buying an additional 41 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Waters by 7.5% in the third quarter. Clearstead Advisors LLC now owns 586 shares of the medical instruments supplier’s stock valued at $176,000 after acquiring an additional 41 shares in the last quarter. Finally, CW Advisors LLC boosted its stake in Waters by 2.0% during the 2nd quarter. CW Advisors LLC now owns 2,112 shares of the medical instruments supplier’s stock valued at $737,000 after acquiring an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Waters from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Evercore initiated coverage on shares of Waters in a research report on Tuesday, February 10th. They set a “hold” rating and a $360.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a research note on Tuesday, February 10th. UBS Group lowered their price objective on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Finally, Morgan Stanley cut their price objective on Waters from $423.00 to $350.00 and set an “equal weight” rating on the stock in a research note on Sunday, February 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Waters currently has an average rating of “Moderate Buy” and a consensus target price of $393.84.

Waters Stock Performance

WAT stock opened at $290.01 on Tuesday. The stock has a market capitalization of $28.45 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 1.97 and a beta of 1.20. The stock’s fifty day moving average is $350.57 and its two-hundred day moving average is $351.53. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.73.

Waters (NYSE:WAT) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The firm had revenue of $932.36 million during the quarter, compared to analyst estimates of $928.17 million. During the same period in the previous year, the business posted $4.10 EPS. Waters’s revenue was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, research analysts predict that Waters Corporation will post 12.86 EPS for the current year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.